Related Experiment Video
Updated: Jun 18, 2026
07:20
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Novel bis-platinum complexes endowed with an improved pharmacological profile
Laura Gatti1, Paola Perego, Roberto Leone
1Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan,Italy.
Molecular Pharmaceutics
|November 19, 2009
Summary
Novel platinum complexes show enhanced stability and potent anticancer activity, overcoming drug resistance and showing promise in preclinical tumor models.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Multinuclear platinum complexes offer unique DNA binding and higher cytotoxicity than mononuclear agents.
- Limitations of earlier platinum compounds include high plasma protein binding and suboptimal drug stability.
- Developing novel platinum-based chemotherapeutics is crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To design and synthesize novel second-generation bis-platinum complexes with improved pharmacokinetic and pharmacodynamic properties.
- To evaluate the stability, cytotoxic potency, and antitumor efficacy of these new compounds.
- To overcome limitations associated with previous multinuclear platinum agents.
Main Methods:
- Synthesis of novel bis-platinum complexes, CT-47518 (bis-capronate) and CT-47463 (bis-butyrate), utilizing alkylcarboxylate leaving groups.
- In vitro assessment of degradation kinetics in human and murine plasma.
- In vitro cytotoxicity assays against various cancer cell lines, including cisplatin- and oxaliplatin-resistant models.
- In vivo evaluation of antitumor efficacy in platinum-refractory tumor xenografts.
Main Results:
- CT-47518 and CT-47463 demonstrated increased stability in human plasma compared to the parent compound CT-3610.
- Both compounds exhibited significant cytotoxic potency, surpassing cisplatin and oxaliplatin.
- The novel complexes effectively overcame resistance mediated by DNA mismatch repair defects.
- Marked antitumor efficacy was observed in platinum-refractory tumor xenografts, showing substantial tumor growth inhibition and delay.
Conclusions:
- The second-generation bis-platinum complexes, CT-47518 and CT-47463, possess improved stability and potent anticancer activity.
- These compounds demonstrate efficacy against platinum-resistant cancers and exhibit promising preclinical antitumor effects.
- CT-47518 and CT-47463 represent attractive candidates for further clinical development in oncology.
Related Concept Videos
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:19Phase II Reactions: Miscellaneous Conjugation Reactions
Phase II biotransformations are detoxification mechanisms that conjugate xenobiotics with endogenous substances, neutralizing their toxicity.
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...